Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 17 Leukemia, Myelomonocytic, Acute 11 Leukemia, Monocytic, Acute 11 Leukemia, Megakaryoblastic, Acute 11 Leukemia, Erythroblastic, Acute 11 Breast Neoplasms 11 Congenital Abnormalities 9 Leukemia 7 Glioblastoma 7 Recurrence 6 Pancreatic Neoplasms 6 Multiple Myeloma 5 Leukemia, Myelomonocytic, Chronic 5 Leukemia, Eosinophilic, Acute 5 Leukemia, Basophilic, Acute 5 Gliosarcoma 5 Carcinoma, Non-Small-Cell Lung 5 Anemia, Refractory, with Excess of Blasts 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Breast Neoplasms, Male 4 Brain Neoplasms 4 Blast Crisis 4 Urinary Bladder Neoplasms 3 Unspecified Adult Solid Tumor, Protocol Specific 3 Thyroid Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neuroblastoma 3 Melanoma 3

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 aflutinib 9 Drug Therapy 9 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × tipifarnib × Clear all

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡